Substance use and poisoning - Articles - Page 8

Substance Use & Poisoning

RNCP selects Redhill's opaganib for evaluation for acute radiation syndrome

March 1, 2023

Redhill Biopharma Ltd.'s opaganib hydrochloride (ABC-294640) has been selected by the Radiation and Nuclear Countermeasures Program (RNCP), of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the nuclear medical countermeasures product development pipeline as a potential treatment for acute radiation syndrome (ARS).

Gloved hand holding powder substance in bag

Substance Use & Poisoning

CSX-1004 blocks fentanyl-induced respiratory depression in nonhuman primates

March 1, 2023

Cessation Therapeutics Inc. has announced outcomes of a new study demonstrating that its anti-fentanyl monoclonal antibody treatment, CSX-1004, may provide robust and durable protection from life-threatening respiratory depression caused by high doses of fentanyl. The findings come from the company’s ongoing series of proof-of-concept studies in nonhuman primates.

Substance Use & Poisoning

Aphiotx describes new PANX1 inhibitors for opioid withdrawal

Feb. 9, 2023

Aphiotx Inc. has identified sulfamoyl benzene derivatives acting as pannexin-1 (PANX1; MRS1) inhibitors reported to be useful for the treatment of opioid withdrawal.

Substance Use and Poisoning

Clearmind completes IND-enabling studies for CMND-100 for alcohol use disorder

Dec. 14, 2022

Clearmind Medicine Inc. has completed IND-enabling studies with its 5-methoxy-2-aminoindane (MEAI)-based lead compound, CMND-100, aimed at treating alcohol use disorder (AUD). The company is preparing for an IND submission early next year to the FDA and the Israeli Ministry of Health to start first-in-human phase I/IIa studies in the U.S. and Israel.

Gastrointestinal

Gut microbiota degrade intestinal nicotine, alleviate smoking-related liver disease

Oct. 19, 2022

By Mar de Miguel

Peking University researchers in collaboration with the NIH have discovered a new biochemical pathway related to a bacterium that eliminates nicotine in the intestine. The findings could lead to new ways to improve nonalcoholic fatty liver disease (NAFLD) in smokers. In addition to the lung and the brain, nicotine can accumulate in the intestine, where the bacteria Bacteroides xylanisolvens could reduce its concentration and the severity of NAFLD. In their study, published in Nature Oct. 19, 2022, the researchers described the enzymes involved in this process and a new undiscovered pathway.

Substance use and poisoning

GATC Health compounds enter preclinical development for fentanyl addiction and opioid use disorders

Oct. 7, 2022

GATC Health Corp. has announced that the new drug candidates discovered by its proprietary artificial intelligence (AI) drug discovery and prediction platform to treat opioid use disorder (OUD) and fentanyl addiction have entered preclinical development.

Substance use and poisoning

Spironolactone shows promise for alcohol abuse disorder in rodents

Oct. 3, 2022

Recent evidence suggests that spironolactone, a mineralocorticoid receptor antagonist, may modulate alcohol seeking and consumption, for which current therapies are limited.

Substance use and poisoning

NIAAA grant supports Epivario's work on ACSS2 inhibition for alcohol use disorder

Sep. 15, 2022

Epivario Inc. has been awarded a grant of nearly $260,000 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to advance research on its proprietary small-molecule inhibitors designed to reduce alcohol craving responses and help people with alcohol use disorder (AUD) prevent relapse.

MultiStem shows benefit in animal model of acute radiation syndome

Aug. 9, 2022

A radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI) has shown that intravenous administration of Athersys' MultiStem (invimestrocel) provided benefit in an animal model of acute radiation syndrome (ARS).